
Rallis India Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 5
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 5- The global agrochemical business experienced rapid growth (from $60-65 billion to $80 billion in two years) but is currently facing inventory overhang and price correction, causing demand compression expected to last through Q3 and the financial year.
- Volume-led growth is a priority, though pricing growth is likely negative in the near term.
- Domestic industry growth is expected to be low single digit with flat to marginally positive volumes.
- International business faces volume declines due to high channel inventories and pricing pressures, with normalization anticipated after Q3 but timing uncertain.
- Seed business growth is positive with strong cotton hybrid sales; efforts continue to reduce seasonality and improve unit economics.
- New product launches, ramp-up of multipurpose plants, and strategic pipeline development aim for steady consistent growth over the coming years.
- Cost and margin management remain priorities to navigate volatile markets and sustain profitability.
See what Rallis India management said on margin guidance — free account, 30 seconds.
Fundraise plans
- No new fundraising through debt or equity is mentioned in the transcript.
- The company has repaid Rs.100 crore of working capital loans during H1 FY24.
- Post this repayment, Rallis India has become a zero-debt company except for a small sales tax deferral loan.
- Capex for the year is envisaged to be around Rs.150 crore, indicating ongoing investments are likely to be funded internally.
- No indication of plans for raising additional capital through equity or new debt issuance was shared during the call.
See what Rallis India management said on order book — free account, 30 seconds.
Capex plans
Yes- The company envisages capex spending of around Rs.150 crore for the year.
- Focus on ramping up the multipurpose plant (MPP) at Dahej.
- Continuous evaluation and potential expansion of capacity for Pendimethalin due to rising demand.
- Investments made over the last few years in R&D, product development, manufacturing, and capabilities aimed at supporting long-term sustainable growth.
- Plans to scale up contract manufacturing business progressively through better utilization of the new multi-purpose plant.
- Introduction of new technical products like Difenoconazole and upcoming commercialization of new CSM products from MPP expected to contribute to growth.
- Investment decisions are made with a long-term perspective, considering over 10-year IRR for projects.
Track Rallis India — get its next earnings analysis in your feed
How does Rallis India rank vs peers in Fertilizers & Agrochemicals?
Pro featureHow does Rallis India rank in Fertilizers & Agrochemicals?
Compare Rallis India against every Fertilizers & Agrochemicals company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Rallis India's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- Madhya Bharat Agro Products (Q2 FY27)
Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo
- Dhansa Labs (Q2 FY27)
1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Aristo Bio-Tech (Q2 FY27)
1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu
- Krishana Phoschem (Q2 FY27)
Q2 FY27 Revenue: ₹703 crore, a 16% year-on-year (YoY) increase (Page 11). Key investor presentation takeaways from Krishana Phoschem Ltd's Q2 FY27 investor pres